Literature DB >> 19197975

Predicting neuroendocrine tumor (carcinoid) neoplasia using gene expression profiling and supervised machine learning.

Ignat Drozdov1, Mark Kidd, Boaz Nadler, Robert L Camp, Shrikant M Mane, Oyvind Hauso, Bjorn I Gustafsson, Irvin M Modlin.   

Abstract

BACKGROUND: A more accurate taxonomy of small intestinal (SI) neuroendocrine tumors (NETs) is necessary to accurately predict tumor behavior and prognosis and to define therapeutic strategy. In this study, the authors identified a panel of such markers that have been implicated in tumorigenicity, metastasis, and hormone production and hypothesized that transcript levels of the genes melanoma antigen family D2 (MAGE-D2), metastasis-associated 1 (MTA1), nucleosome assembly protein 1-like (NAP1L1), Ki-67 (a marker of proliferation), survivin, frizzled homolog 7 (FZD7), the Kiss1 metastasis suppressor (Kiss1), neuropilin 2 (NRP2), and chromogranin A (CgA) could be used to define primary SI NETs and to predict the development of metastases.
METHODS: Seventy-three clinically and World Health Organization pathologically classified NET samples (primary tumor, n = 44 samples; liver metastases, n = 29 samples) and 30 normal human enterochromaffin (EC) cell preparations were analyzed using real-time polymerase chain reaction. Transcript levels were normalized to 3 NET housekeeping genes (asparagine-linked glycosylation 9 or ALG9, transcription factor CP2 or TFCP2, and zinc finger protein 410 or ZNF410) using geNorm analysis. A predictive gene-based model was constructed using supervised learning algorithms from the transcript expression levels.
RESULTS: Primary SI NETs could be differentiated from normal human EC cell preparations with 100% specificity and 92% sensitivity. Well differentiated NETs (WDNETs), well differentiated neuroendocrine carcinomas, and poorly differentiated NETs (PDNETs) were classified with a specificity of 78%, 78%, and 71%, respectively; whereas poorly differentiated neuroendocrine carcinomas were misclassified as either WDNETs or PDNETs. Metastases were predicted in all cases with 100% sensitivity and specificity.
CONCLUSIONS: The current results indicated that gene expression profiling and supervised machine learning can be used to classify SI NET subtypes and accurately predict metastasis. The authors believe that the application of this technique will facilitate accurate molecular pathologic delineation of NET disease, better define its extent, facilitate the assessment of prognosis, and provide a guide for the identification of appropriate strategies for individualized patient treatment.

Entities:  

Mesh:

Year:  2009        PMID: 19197975      PMCID: PMC2743551          DOI: 10.1002/cncr.24180

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  39 in total

1.  Human genome studies expected to revolutionize cancer classification.

Authors:  J Stephenson
Journal:  JAMA       Date:  1999-09-08       Impact factor: 56.272

2.  Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors.

Authors:  Mark Kidd; Geeta Eick; Michael D Shapiro; Robert L Camp; Shrikant M Mane; Irvin M Modlin
Journal:  Cancer       Date:  2005-01-15       Impact factor: 6.860

3.  Transcriptional regulation of KiSS-1 gene expression in metastatic melanoma by specificity protein-1 and its coactivator DRIP-130.

Authors:  D C Mitchell; L J Stafford; D Li; M Bar-Eli; M Liu
Journal:  Oncogene       Date:  2006-09-11       Impact factor: 9.867

4.  Tree-based analysis of microarray data for classifying breast cancer.

Authors:  Heping Zhang; Chang-Yung Yu
Journal:  Front Biosci       Date:  2002-05-01

5.  GeneChip, geNorm, and gastrointestinal tumors: novel reference genes for real-time PCR.

Authors:  Mark Kidd; Boaz Nadler; Shrikant Mane; Geeta Eick; Maximillian Malfertheiner; Manish Champaneria; Roswitha Pfragner; Irvin Modlin
Journal:  Physiol Genomics       Date:  2007-04-24       Impact factor: 3.107

Review 6.  The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification.

Authors:  Günter Klöppel; Aurel Perren; Philipp U Heitz
Journal:  Ann N Y Acad Sci       Date:  2004-04       Impact factor: 5.691

7.  Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.

Authors:  WeiDe Zhong; Jinyu Peng; HuiChan He; Dinglan Wu; ZhaoDong Han; XueCheng Bi; QiShan Dai
Journal:  Clin Invest Med       Date:  2008       Impact factor: 0.825

8.  Classification of prostatic carcinoma with artificial neural networks using comparative genomic hybridization and quantitative stereological data.

Authors:  Torsten Mattfeldt; Hans-Werner Gottfried; Hubertus Wolter; Volker Schmidt; Hans A Kestler; Johannes Mayer
Journal:  Pathol Res Pract       Date:  2003       Impact factor: 3.250

9.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

10.  A comparative study of different machine learning methods on microarray gene expression data.

Authors:  Mehdi Pirooznia; Jack Y Yang; Mary Qu Yang; Youping Deng
Journal:  BMC Genomics       Date:  2008       Impact factor: 3.969

View more
  24 in total

Review 1.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Authors:  Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin
Journal:  Langenbecks Arch Surg       Date:  2011-01-28       Impact factor: 3.445

Review 2.  EGFR/TGFα and TGFβ/CTGF Signaling in Neuroendocrine Neoplasia: Theoretical Therapeutic Targets.

Authors:  M Kidd; S Schimmack; B Lawrence; D Alaimo; I M Modlin
Journal:  Neuroendocrinology       Date:  2012-06-15       Impact factor: 4.914

3.  Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro.

Authors:  Yash Somnay; Kevin Simon; April D Harrison; Selvi Kunnimalaiyaan; Herbert Chen; Muthusamy Kunnimalaiyaan
Journal:  Anticancer Drugs       Date:  2013-01       Impact factor: 2.248

4.  Epidemiology of small bowel carcinoids in a defined population.

Authors:  Kalle Landerholm; Sture Falkmer; Johannes Järhult
Journal:  World J Surg       Date:  2010-07       Impact factor: 3.352

Review 5.  Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how?

Authors:  Prasanna Santhanam; Sangeeta Chandramahanti; Alexander Kroiss; Run Yu; Philippe Ruszniewski; Rakesh Kumar; David Taïeb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-13       Impact factor: 9.236

6.  Assessment of performance of survival prediction models for cancer prognosis.

Authors:  Hung-Chia Chen; Ralph L Kodell; Kuang Fu Cheng; James J Chen
Journal:  BMC Med Res Methodol       Date:  2012-07-23       Impact factor: 4.615

7.  Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors.

Authors:  Tao Cui; Monica Hurtig; Graciela Elgue; Su-Chen Li; Giulia Veronesi; Ahmed Essaghir; Jean-Baptiste Demoulin; Giuseppe Pelosi; Mohammad Alimohammadi; Kjell Öberg; Valeria Giandomenico
Journal:  PLoS One       Date:  2010-12-30       Impact factor: 3.240

Review 8.  Artificial intelligence in small intestinal diseases: Application and prospects.

Authors:  Yu Yang; Yu-Xuan Li; Ren-Qi Yao; Xiao-Hui Du; Chao Ren
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

9.  Assessment of reproducibility of cancer survival risk predictions across medical centers.

Authors:  Hung-Chia Chen; James J Chen
Journal:  BMC Med Res Methodol       Date:  2013-02-20       Impact factor: 4.615

10.  The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood.

Authors:  Irvin M Modlin; Ignat Drozdov; Mark Kidd
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.